Proteasome inhibitors in mantle cell lymphoma

Best Practice and Research: Clinical Haematology

Volumn 25, Issue 2, 2012, Pages 133-141

  Holkova, Beata ^a,b   Grant, Steven ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

bortezomib; carfilzomib; mantle cell lymphoma; non Hodgkin's lymphoma; proteasome inhibitor

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CYTARABINE; DEXAMETHASONE; IBRITUMOMAB TIUXETAN; OBATOCLAX; PANOBINOSTAT; PROTEASOME INHIBITOR; RITUXIMAB; ROMIDEPSIN; VORINOSTAT;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84862215014     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2012.04.007     Document Type: Review

References (65)

1. A. Majlis, W.C. Pugh, and M.A. Rodriguez Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants J Clin Oncol 15 4 1997 Apr 1664 1671 (Pubitemid 27167407)
2. A. Herrmann, E. Hoster, and T. Zwingers Improvement of overall survival in advanced stage mantle cell lymphoma J Clin Oncol 27 4 2009 Feb 1 511 518
3. O.M. Howard, J.G. Gribben, and D.S. Neuberg Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival J Clin Oncol 20 5 2002 Mar 1 1288 1294 (Pubitemid 34177435)
4. D.D. Wilder, J.L. Ogden, and V.K. Jain A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma Clin Lymphoma 1 4 2001 Mar 285 292 (Pubitemid 32331684)
5. M. Jermann, L.M. Jost, and C. Taverna Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study Ann Oncol 15 3 2004 Mar 511 516 (Pubitemid 38444559)
6. J.E. Romaguera, L.E. Fayad, and L. Feng Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma Br J Haematol 150 2 2010 Jul 200 208
7. F. Lefrere, A. Delmer, and F. Suzan Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study Leukemia 16 4 2002 Apr 587 593 (Pubitemid 34449738)
8. I.F. Khouri, J. Romaguera, and H. Kantarjian Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma J Clin Oncol 16 12 1998 Dec 3803 3809 (Pubitemid 29001533)
9. R.I. Fisher, S.H. Bernstein, and B.S. Kahl Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma J Clin Oncol 24 30 2006 Oct 20 4867 4874 (Pubitemid 46655613)
10. A. Goy, A. Younes, and P. McLaughlin Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma J Clin Oncol 23 4 2005 Feb 1 667 675 (Pubitemid 46224166)
11. O.A. O'Connor, J. Wright, and C. Moskowitz Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma J Clin Oncol 23 4 2005 Feb 1 676 684 (Pubitemid 46237441)
12. J.B. Almond, and G.M. Cohen The proteasome: a novel target for cancer chemotherapy Leukemia 16 4 2002 Apr 433 443 (Pubitemid 34449723)
13. A. Nencioni, F. Grunebach, and F. Patrone Proteasome inhibitors: antitumor effects and beyond Leukemia 21 1 2007 Jan 30 36 (Pubitemid 44921831)
14. D.J. Kuhn, S.A. Hunsucker, and Q. Chen Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors Blood 113 19 2009 May 7 4667 4676
15. A.M. Ruschak, M. Slassi, and L.E. Kay Novel proteasome inhibitors to overcome bortezomib resistance J Natl Cancer Inst 103 13 2011 Jul 6 1007 1017
16. B. An, R.H. Goldfarb, and R. Siman Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts Cell Death Differ 5 12 1998 Dec 1062 1075 (Pubitemid 29008220)
17. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 5 2011 Mar 4 646 674
18. J.H. Lin, H. Li, and D. Yasumura IRE1 signaling affects cell fate during the unfolded protein response Science 318 5852 2007 Nov 9 944 949 (Pubitemid 350098984)
19. S.T. Nawrocki, J.S. Carew, and M.S. Pino Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells Cancer Res 66 7 2006 Apr 1 3773 3781
20. A.H. Lee, N.N. Iwakoshi, and K.C. Anderson Proteasome inhibitors disrupt the unfolded protein response in myeloma cells Proc Natl Acad Sci U S A 100 17 2003 Aug 19 9946 9951 (Pubitemid 37087048)
21. Y.H. Ling, L. Liebes, and Y. Zou Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells J Biol Chem 278 36 2003 Sep 5 33714 33723 (Pubitemid 37553204)
22. C. Yu, M. Rahmani, and P. Dent The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib Exp Cell Res 295 2 2004 May 1 555 566 (Pubitemid 38490507)
23. G. Roue, P. Perez-Galan, and A. Mozos The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78 Blood 117 4 2011 Jan 27 1270 1279
24. T. Hideshima, D. Chauhan, and P. Richardson NF-kappa B as a therapeutic target in multiple myeloma J Biol Chem 277 19 2002 May 10 16639 16647 (Pubitemid 34967682)
25. T. Hideshima, H. Ikeda, and D. Chauhan Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells Blood 114 5 2009 Jul 30 1046 1052
26. F. Luciano, A. Jacquel, and P. Colosetti Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function Oncogene 22 43 2003 Oct 2 6785 6793 (Pubitemid 37372218)
27. J. Adams The proteasome: a suitable antineoplastic target Nat Rev Cancer 4 5 2004 May 349 360 (Pubitemid 38579481)
28. Z. Xia, M. Dickens, and J. Raingeaud Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis Science 270 5240 1995 Nov 24 1326 1331
29. S.A. Vaziri, J. Hill, and K. Chikamori Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin Mol Cancer Ther 4 12 2005 Dec 1880 1890 (Pubitemid 43056971)
30. A.M. Roccaro, T. Hideshima, and N. Raje Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells Cancer Res 66 1 2006 Jan 1 184 191 (Pubitemid 43166024)
31. J. Adams The development of proteasome inhibitors as anticancer drugs Cancer Cell. 5 5 2004 May 417 421 (Pubitemid 38610244)
32. D.J. Kuhn, Q. Chen, and P.M. Voorhees Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma Blood 110 9 2007 Nov 1 3281 3290 (Pubitemid 350106321)
33. D. Chauhan, L. Catley, and G. Li A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib Cancer Cell. 8 5 2005 Nov 407 419 (Pubitemid 41579835)
34. D. Chauhan, T. Hideshima, and K.C. Anderson A novel proteasome inhibitor NPI-0052 as an anticancer therapy Br J Cancer 95 8 2006 Oct 23 961 965 (Pubitemid 44606819)
35. P. Perez-Galan, G. Roue, and N. Villamor The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status Blood 107 1 2006 Jan 1 257 264 (Pubitemid 43053550)
36. E.G. Rizzatti, H. Mora-Jensen, and M.A. Weniger Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways Leuk Lymphoma 49 4 2008 Apr 798 808 (Pubitemid 351517227)
37. P. Perez-Galan, G. Roue, and N. Villamor The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak Blood 109 10 2007 May 15 4441 4449 (Pubitemid 46743414)
38. L. Paoluzzi, M. Gonen, and G. Bhagat The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies Blood 112 7 2008 Oct 1 2906 2916
39. O. Weigert, A. Pastore, and M. Rieken Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma Leukemia 21 3 2007 Mar 524 528
40. M. Wang, X.H. Han, and L. Zhang Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo Leukemia 22 1 2008 Jan 179 185
41. C. Yu, M. Rahmani, and D. Conrad The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571 Blood 102 10 2003 Nov 15 3765 3774 (Pubitemid 37409399)
42. T. Hideshima, J.E. Bradner, and J. Wong Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma Proc Natl Acad Sci U S A 102 24 2005 Jun 14 8567 8572 (Pubitemid 40862776)
43. T. Hideshima, P.G. Richardson, and K.C. Anderson Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma Mol Cancer Ther 10 11 2011 Nov 2034 2042
44. U. Heider, I. von Metzler, and M. Kaiser Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma Eur J Haematol 80 2 2008 Feb 133 142
45. L. Paoluzzi, L. Scotto, and E. Marchi Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma Clin Cancer Res 16 2 2010 Jan 15 554 565
46. R. Rao, S. Nalluri, and W. Fiskus Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells Clin Cancer Res 16 19 2010 Oct 1 4742 4754
47. G. Dasmahapatra, D. Lembersky, and L. Kramer The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo Blood 115 22 2010 Jun 3 4478 4487
48. G. Dasmahapatra, D. Lembersky, and M.P. Son Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo Mol Cancer Ther 10 9 2011 Sep 1686 1697
49. P. Perez-Galan, H. Mora-Jensen, and M.A. Weniger Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation Blood 117 2 2011 Jan 13 542 552
50. S.J. Strauss, L. Maharaj, and S. Hoare Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity J Clin Oncol 24 13 2006 May 1 2105 2112 (Pubitemid 46622122)
51. A. Belch, C.T. Kouroukis, and M. Crump A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150 Ann Oncol 18 1 2007 Jan 116 121 (Pubitemid 46152510)
52. A. Goy, S.H. Bernstein, and B.S. Kahl Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study Ann Oncol 20 3 2009 Mar 520 525
53. P.G. Richardson, B. Barlogie, and J. Berenson A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 26 2003 Jun 26 2609 2617 (Pubitemid 36741588)
54. S. Jagannath, B. Barlogie, and J. Berenson A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma Br J Haematol 127 2 2004 Oct 165 172 (Pubitemid 39371809)
55. P. Moreau, H. Pylypenko, and S. Grosicki Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study Lancet Oncol 12 5 2011 May 431 440
56. R.R. Furman, P. Martin, and J. Ruan Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma Cancer 116 23 2010 Dec 1 5432 5439
57. J. Ruan, P. Martin, and R.R. Furman Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma J Clin Oncol 29 6 2011 Feb 20 690 697
58. J.E. Romaguera, L.E. Fayad, and P. McLaughlin Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma Br J Haematol 151 1 2010 Oct 47 53
59. O. Weigert, E. Weidmann, and R. Mueck A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study Leuk Lymphoma 50 5 2009 May 716 722
60. P.M. Barr, P. Fu, and H.M. Lazarus Phase I dose escalation study of fludarabine, bortezomib, and rituximab for relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma J Clin Oncol 2008 ASCO Annual Meeting Proceedings
61. L. Alinari, V.L. White, and C.T. Earl Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma MAbs 1 1 2009 Jan-Feb 31 40
62. ® ) in patients with relapsed or refractory B-Cell non-Hodgkin lymphoma (NHL) Blood 2008 ASH Annual Meeting Abstracts
63. Holkova B, Perkins EB, Sokol L, Richards KL, Parekh S, Elstrom R, et al. A phase II trial of bortezomib and vorinostat in mantle cell lymphoma and diffuse large B-Cell lymphoma. Blood (ASH Annual Meeting Abstracts); San Diego, CA 2011.
64. A. Goy, P. Ford, and T. Feldman A phase 1 trial of the pan Bcl-2 Family inhibitor obatoclax mesylate (GX15-070) in combination with bortezomib in patients with relapsed/refractory mantle cell lymphoma 110 2007 2569
65. K. Dunleavy, S. Pittaluga, and M.S. Czuczman Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma Blood 113 24 2009 Jun 11 6069 6076